Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain

Vaccine

Volumn 29, Issue 8, 2011, Pages 1529-1533

  Farnsworth, Aaron ^a   Cyr, Terry D ^a   Li, Changgui ^b   Wang, Junzhi ^b   Li, Xuguang ^a  

^a HEALTH CANADA   (Canada)

^b NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

Author keywords

H1N1 2009; Influenza; Vaccine stability

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE;

ANTIGENICITY; ARTICLE; DRUG POTENCY; DRUG STABILITY; IN VITRO STUDY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS STRAIN;

EID: 79952702297     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.120     Document Type: Article

References (18)

1. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010;362:1708-19.
2. National Institutes of Health, Clinical trials. http://clinicaltrials.gov/; 2010.
3. Health Canada. New expiry date for unused adjuvanted H1N1 vaccine. Information update, vol. 2010, Ottawa. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/2010/201054-eng.php; 2010.
4. Minnesota Department of Health. Vaccine recalls. http://www.health.state.mn.us/divs/idepc/diseases/flu/hcp/vaccine/recalls.html; 2010.
5. Therapeutic Goods Administration, Department of Health and Ageing. Withdrawl of Panvax Junior. http://www.tga.gov.au/alerts/medicines/panvax-jr-withdrawal.htm; 2010.
6. Creskey MC, Smith DG, Cyr TD. Strain identification of commercial influenza vaccines by mass spectrometry. Anal Biochem 2010.
7. Gravel C, Li C, Wang J, Hashem AM, Jaentschke B, Xu KW, et al. Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neu-raminidases using antibodies targeting the universally conserved sequences. Vaccine 2010;28:5774-84.
8. Silva JC, Denny R, Dorschel C, Gorenstein MV, Li GZ, Richardson K, et al. Simultaneous qualitative and quantitative analysis of the Escherichia coli proteome: a sweet tale. Mol Cell Proteomics 2006;5: 589-607.
9. Xu R, Ekiert DC, Krause JC, Hai R, Crowe Jr JE, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010;328:357-60.
10. Guex N,Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer:an environmentfor comparative protein modeling. Electrophoresis 1997;18:2714-23.
11. Ruigrok RW, Martin SR, Wharton SA, Skehel JJ, Bayley PM, Wiley DC. Confor-mational changes in the hemagglutinin of influenza virus which accompany heat-induced fusion of virus with liposomes. Virology 1986;155:484-97.
12. Korte T, Ludwig K, Huang Q, Rachakonda PS, Herrmann A. Conformational change of influenza virus hemagglutinin is sensitive to ionic concentration. Eur Biophys J 2007;36:327-35.
13. Godley L, Pfeifer J, Steinhauer D, Ely B, Shaw G, Kaufmann R, et al. Introduction of intersubunit disulfide bonds in the membrane-distal region of the influenza hemagglutinin abolishes membrane fusion activity. Cell 1992;68:635-45.
14. Rachakonda PS, Veit M, Korte T, Ludwig K, Böttcher C, Huang Q, et al. The relevance of salt bridges for the stability of the influenza virus hemagglutinin. FASEB J 2007;21:995-1002.
15. Iwata T, Fukuzawa K, Nakajima K, Aida-Hyugaji S, Mochizuki Y, Watanabe H, et al. Theoretical analysis of binding specificity of influenza viral hemagglutinin toavian and human receptors basedonthe fragmentmolecular orbitalmethod. Comput Biol Chem 2008;32:198-211.
16. Daniels PS, Jeffries S, Yates P, Schild GC, Rogers GN, Paulson JC, et al. The receptor-binding and membrane-fusion properties of influenza virus variants selected using anti-haemagglutinin monoclonal antibodies. EMBO J 1987;6:1459-65.
17. Bosch BJ, Bodewes R, de Vries RP, Kreijtz JH, Bartelink W, van Amerongen G, et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J Virol 2010;84:10366-74.
18. Food and Drug Administration Vaccines, Blood & Biologics. Influenza vaccine for the 2010-2011 season http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/post-marketactivities/lotreleases/ucm202750.htm; 2010.